Comparison
of anti-vascular endothelial growth factors, laser treatments and a combination
of the both for treatment of central retinal vein occlusion
Yoav
Y. Pikkel1, Adi Sharabi-Nov2, Itzchak Beiran3,4,
Joseph Pikkel5,6
1Tzameret
Medical Track, Hebrew University, Jerusalem 91120,
Israel
2Research
Wing, Ziv Medical Center, Safed, Israel and Tel-Hai Academic College, Kiryat Shmona 12208, Israel
3Department
of Ophthalmology, Rambam Medical Center, Haifa 3525408,
Israel
4The B.
Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa 3525427, Israel
5Department
of Ophthalmology, Ziv Medical Center, Safed 13100,
Israel
6Bar
Ilan University, Faculty of Medicine, Safed 13101,
Israel
Correspondence to: Joseph Pikkel. Department
of Ophthalmology, Ziv Medical Center, Safed 13100, Israel. pikkel.86@gmail.com
Received:
2014-12-01
Accepted: 2015-05-27
Abstract
AIM: To
compare changes in visual acuity and macular edema in patients with central
retinal vein occlusion (CRVO) treated with intravitreal injections of
bevacizumab, macular
grid photocoagulation combined with pan retinal photocoagulation (PRP), or both (bevacizumab+grid+PRP).
METHODS: Our
study is a retrospective cohort clinical study that examined patients that
suffered from ischemic CRVO with macular edema.
Study inclusion criteria were ischemic
CRVO with macula edema and the availability of complete medical records for at
least 12mo after treatment. Excluded were patients with diabetes or any other
retinal disease. We reviewed the medical records of patients treated in
one ophthalmology department-comparing
changes in visual acuity and macular edema in patients treated with
intravitreal injections of bevacizumab vs
those that were treated with macular
grid photocoagulation and PRP or both. The main outcome measures were the
differences in best corrected visual acuity (BCVA) and in macular thickness, as
assessed by optical coherence tomography, between the enrollment and the final
follow up visits.
RESULTS: Sixty-five patients met inclusion criteria.
There were no statistically significant differences among the three groups in
the mean changes in macular thickness as measured by ocular coherence
tomography (131.5±41.2, 108.6±29.2, and 121.1±121.1, P=0.110),
or in visual acuity (0.128±0.077, 0.088±0.057, and 0.095±0.065),
for intravitreal
injections, macular grid photocoagulation+PRP
and a combination of the treatments, respectively, P=0.111. The
proportions of patients with macular edema after treatment were:
26.1%, 28.6%, and 14.3%,
respectively, P=0.499.
CONCLUSION: Similar benefit was observed for
intravitreal injections, laser photocoagulation, or a combined regimen in the
treatment of CRVO. A non-statistically significant trend for reduction in
macular edema was observed following combined treatment.
KEYWORDS: bevacizumab; grid
laser photocoagulation; macular edema;
optical coherence tomography; retinal
vein occlusion
Citation: Pikkel YY,
Sharabi-Nov A, Beiran I, Pikkel J. Comparison of anti-vascular endothelial
growth factors, laser treatments and a combination of the both for treatment of
central retinal vein occlusion. Int J Ophthalmol 2016;9(3):431-433
INTRODUCTION
Central retinal vein occlusion (CRVO)
carries a potential risk for blindness. Decreased visual acuity (VA) in CRVO may result from macular edema
(ME). CRVO associated ME has been reported to respond favorably to intravitreal
injections of anti-vascular endothelial growth factors (VEGF) and pan retinal
laser photocoagulation[1-4]. Though
macular grid laser treatment is not indicated as a treatment for ME due to CRVO it was found as beneficial
in cases of ME due to branch retinal vein occlusion and at least once was found
as effective in ME due to CRVO[5]. Other medical and surgical therapies
that have been investigated as treatments for CRVO associated ME failed to
achieve ME absorption or caused undesirable side effects[6-13].
Thus, the currently accepted treatment for CRVO associated ME is anti-VEGF
intravitreal injections. Subsequent application of macular grid
photocoagulation and pan retinal photocoagulation (PRP) was suggested when such
treatment fails[14]. Several studies[3-4,13,15] that
compared the effectiveness of intravitreal anti-VEGF antibody injections to macular
grid photocoagulation
demonstrated superiority of intravitreal anti-VEGF antibody injections as
first line treatment.
Nevertheless, widely excepted guidelines for optimal treatment do not yet
exist. In the present study we compared changes in VA and in macular thickness,
and in the proportions of patients with ME, following treatment by intravitreal
anti-VEGF
injections or by macular grid photocoagulation or by a combination of these two treatments.
SUBJECTS AND METHODS
The
medical records of all patients treated for ischemic CRVO associated ME in the
Ziv Medical Center Israel from January 1, 2010 to December 31, 2012 were
reviewed. The
study was approved by the local bio-ethical committee (0063-13 ZIV). Ischemic
CRVO was defined as severe visual loss (6/60 or less), extensive retinal
hemorrhages and cotton-wool spots, and poor perfusion to retina as observed in
fleuroscein angiography.
Data regarding age, gender, general health condition, primary VA, final VA and
ME parameters were collected. Patients were divided into 3 groups for analysis,
according to 3 treatment regimens that were administered during the study time: 1) Patients
treated with intravitreal bevacizumab injections only (one injection per month
for the first 3mo), followed by injections according to clinical examination
and optical coherence tomography (OCT) results. 2) Patients treated with macular grid
photocoagulation and PRP only. 3) Patients treated with one
intravitreal bevacizumab injection within one month of diagnosis, followed by
macular grid photocoagulation and PRP and then followed by intravitreal
bevacizumab injections according to clinical examination and OCT results.
Intravitreal injections of
bevacizumab were preformed within one month from diagnosis in all groups.
Intravitreal bevacizumab injections according to clinical examination and OCT
results were continued until resolution of macular edema. In cases of
persistent ME, intravitreal injections were stopped
after 3 injections that did not cause any change in ME
as shown in OCT.
The
main outcome measures were the differences in best corrected visual acuity (BCVA)
and in macular thickness, as assessed by OCT, between the enrollment and the
final follow up visits. Inclusion criteria were ischemic CRVO with ME and the
availability of complete follow up data for at least 12mo after the last
injection or after macular grid photocoagulation.
Statistical Analysis Differences
among mean values of patients' age, ΔOCT and ΔVA among the 3 treatment groups
were calculated by the ANOVA test. Differences in the numbers of injections
were calculated by the independent sample t-test.
The correlation between the proportion of patients with ME and the type of
treatment was calculated by the Chi-square nonparametric test.
RESULTS
Of 79 patients who suffered from ME due
to ischemic CRVO during the study period, 6 were excluded due to diabetic retinopathy.
Of the rest 73 patients, complete medical records with at least 12mo follow-up
were available for 65: 23 in
the injected group, 21 in the macular grid photocoagulation + PRP group and 21
in the combined therapy group. At baseline, mean age, primary VA and macular thickness were similar
among the groups (Table 1).
Table 1 Comparison of outcomes among
treatment groups
Variables |
Anti-VEGF injections (n=23) |
Laser
grid+PRP (n=21) |
Anti-VEGF injections+laser grid+PRP
(n=21) |
P |
Age (a) |
64.0±9.1 |
62.9±10.0 |
66.9±8.8 |
0.360 |
ΔOCT |
131.5±41.2 |
108.6±29.2 |
121.1±34.5 |
0.110 |
ΔVA |
0.128±0.077 |
0.088±0.057 |
0.095±0.065 |
0.111 |
No.
of injections |
3.5±1.2 |
- |
3.2±1.1 |
0.365 |
ME no.
(%) |
6
(26.1) |
6
(28.6) |
3
(14.3) |
0.499 |
SD: Standard deviation; OCT: Optical
coherence tomography; VA: Visual acuity; ME: Macular edema; No.: Number.
The mean number of intravitreal
injections was similar in the two groups of patients who received injections
(3.5 vs 3.2; Table
1). In all three groups there was an improvement in VA
and reduction of macular thickness, with no statistically significant differences
among the groups (Table 1). The rate of residual ME
was lower in the combined treatment group comparing to the injection only, and
grid+PRP groups: 14.3%, 26.1%, and 28.6%, respectively, P =0.499 (Table 1).
DISCUSSION
Treatment of ME
secondary to CRVO is challenging and sometimes frustrating. Widely accepted
guidelines for treatment are not currently available[7]. While both intravitreal bevacizumab injections and macular grid
photocoagulation+PRP, have demonstrated effectiveness, some ophthalmologists
prefer one of the treatments over the other. Comparing outcomes of combined
treatment in 19 patients who suffered from ME due to branch retinal vein
occlusion and 9 who suffered from ME due to CRVO, was done by Ogino et al[15] They concluded that grid photocoagulation
combined with intravitreal bevacizumab has
a substantial effect in reducing recurrent ME
associated with retinal vein occlusion, but the effect on VA is limited. Shah and
Shah[16] treated nine patients with ME
secondary to CRVO with a single intravitreal injection of bevacizumab within
10d from diagnosis, followed 3wk later by pan retinal and macular grid
photocoagulation. They
concluded that early intravitreal bevacizumab therapy followed
by pan retinal and macular grid
laser
may provide visually and anatomically favorable results for treatment of CRVO. They stated
that the combined early treatment may also obviate the need for repeated
injection[16-17]. These two studies did not compare treatment
strategies. In the present study the number of injections needed was similar
with or without grid laser; however, not all of the patients received an
intravitreal injection within 10d from the CRVO event. All three treatment
strategies resulted in improvement. Though there was no statistically
significant difference in VA
improvement or in macular thickness reduction among the three groups, better
macular edema tended to resolve more often in the combined treatment compared
to the other two groups. Though grid laser treatment is not recommended for
treatment of CRVO related ME, in our retrospective study the combination of
grid laser with PRP and/or bevacizumab
injections did show some improvement in ME
reabsorption and reducing macular thickness. A larger sample size is needed to
confirm these findings.
Intravitreal bevacizumab injection, macular grid
photocoagulation+PRP and a combination of these treatments are all effective in
treating ME secondary to CRVO. In this study no statistically
significant differences in VA
improvement or in macular thickness reduction were found between the three
groups. Large scale studies are needed to investigate if the tendency
demonstrated herein for better results in the combination therapy group reaches
statistical significance.
ACKNOWLEDGEMENTS
Conflicts of Interest: Pikkel YY, None; Sharabi-Nov A, None; Beiran I, None; Pikkel J,
None
REFERENCES
1 Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence
of retinal vein occlusion: the Beaver Dam Eye Study. <ii>Arch
Ophthalmol</ii> 2008;126:513-518. [CrossRef] [PubMed]
2 A randomised clinical trial of early
panretinal photocoagulation for ischaemic central vein occlusion. The Central
Retinal Vein Occlusion Study Group N report.<ii> Ophthalmology</ii>
1995;102(10): 1434-1444. [CrossRef]
3 Montoro-García S, Lip PL, Chan CC,
Lip GY. Soluble vascular endothelial growth factor receptor (VEGFR)-2 in
macular oedema-a mechanism for regulating angiogenesis? <ii>Br J
Ophthalmol</ii> 2011;95(6):757-758. [CrossRef]
[PubMed]
4 Lip PL, Chatterjee S, Caine GJ,
Hope-Ross M, Gibson J, Blann AD, Lip GY.. Plasma vascular endothelial growth
factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic
retinopathy: effects of laser photocoagulation and angiotensin receptor
blockade. <ii>Br J Ophthalmol</ii> 2004;88(12):1543-1546. [CrossRef]
[PubMed] [PMC free article]
5 Glacet-Bernard A. Mahadavi KN. Coscas
G. Zourdani A. Fardeau C. Macular grid photocoagulation in persistent macular
edema due to central retinal vein occlusion. <ii>Eur J
Ophthalmol</ii> 1994;4(3):166-174. [PubMed]
6 Ai E, Yang SS. Venous occlusive
disease: the latest in current management. <ii>Retina</ii>
2006;26(6 Suppl):S63-S64. [CrossRef]
7 Höh AE, Schaal KB, Dithmar S. Central
and branch retinal vein occlusion. Current strategies for treatment in Germany,
Austria and Switzerland. <ii>Ophthalmologe </ii> 2007;104(4):
290-294. [CrossRef] [PubMed]
8 Park CH, Scott AW, Fekrat S. Effect
of oral pentoxifylline on cystoid macular edema associated with central retinal
vein occlusion. <ii>Retina </ii> 2007;27(8):1020-1025. [CrossRef] [PubMed]
9 Wright JK, Franklin B, Zant E.
Clinical case report: treatment of a central retinal vein occlusion with hyperbaric
oxygen. <ii>Undersea Hyperbar Med</ii> 2007;34(5):315-319. [PubMed]
10 Arevalo JF, Garcia RA, Wu L,
<ii>et al</ii>. Radial optic neurotomy for central retinal vein
occlusion: results of the Pan-American Collaborative Retina study group
(PACORES). <ii>Retina</ii> 2008;28(8):1044-1052. [CrossRef] [PubMed]
11 Park DH, Kim IT. Long-term effects
of vitrectomy and internal limiting membrane peeling for macular edema
secondary to central retinal vein occlusion and hemiretinal vein occlusion.
<ii>Retina</ii> 2010;30(1):117-124. [CrossRef] [PubMed]
12 Weiss JN, Bynoe LA. Injection of
tissue plasminogen activator into a branch retinal vein in eyes with central
retinal vein occlusion. <ii>Ophthalmology</ii> 2001;108(12):2249-2257.
[CrossRef]
13 Pielen A, Feltgen N, Isserstedt C,
Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy
in macular edema due to branch and central retinal vein occlusion: a systematic
review. <ii>PLoS One</ii> 2013;8(10):e78538. [CrossRef] [PubMed]
[PMC free article]
14 Coscas G, Loewenstein A, Augustin A,
Bandello F, Battaglia Parodi M, Lanzetta P, Monés J, de Smet M, Soubrane G,
Staurenghi G. Management of retinal vein occlusion-consensus document.
<ii>Ophthalmologica</ii> 2011;226(1):4-28.<bb> [CrossRef]
[PubMed]
</bb>15 Ogino K, Tsujikawa A,
Murakami T, Muraoka Y, Kurashige Y, Yoshimura N. Grid photocoagulation combined
with intravitreal bevacizumab for recurrent macular edema associated with
retinal vein occlusion. <ii>Clin Ophthalmol </ii> 2011;5:1031-1036.
[PMC free article]
[PubMed]
16 Shah NJ. Shah UN. Long-term effect
of early intervention with single intravitreal injection of bevacizumab
followed by panretinal and macular grid laser photocoagulation in central
retinal vein occlusion (CRVO) with macular edema: a pilot study. <ii>Eye
(Lond)</ii> 2011;25(2);239-244. [CrossRef]
[PubMed] [PMC free article]
17 Rosenfeld PJ, Fung AE, Puliafito CA.
Optical coherence tomography findings after an intravitreal injection of
bevacizumab (avastin) for macular edema from central retinal vein
occlusion.<ii> Ophthalmic Surg Lasers Imaging</ii>
2005;36(4):336-339.<bb> [PubMed]
[Top]